Table 1.
Descritptive characteristics of study population, stratified by study, number of vaccine doses received and vaccine arm using available data in the total vaccinated cohort among women with 12 or more months of follow-up time (T-TVC).
| Costa Rica Vaccine Trial | PATRICIA | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 dose | 2 doses | 3 doses | 1 dose | 2 doses | 3 doses | |||||||
| HPV N=192 |
Control N=185 |
HPV N=419 |
Control N=379 |
HPV N=2927 |
Control N=2992 |
HPV N=109 |
Control N=79 |
HPV N=216 |
Control N=219 |
HPV N=8296 |
Control N=8340 |
|
| Age at enrollment1 | 21·3 (2·3) | 21·4 (2·4) | 20·9 (2·3) | 20·9 (2·4) | 21·1 (2·3) | 21·1 (2·3) | 21·3 (2·7) | 21·0 (3·0) | 21·1 (2·9) | 21·3 (2·8) | 19·9 (3·1) | 19·9 (3·1) |
| Follow-up time (months)1 | 54·2 (8·8) | 54·5 (9·1) | 54·2 (10·0) | 54·1 (10·3) | 54·1 (8·3) | 54·3 (8·3) | 43·8 (9·3) | 43·1 (9·4) | 43·0 (9·2) | 43·1 (8·6) | 44·9 (7·2) | 44·9 (7·4) |
| #non-vaccine study visits1 | 4·7 (1·5) | 4·5 (1·5) | 4·3 (1·3) | 4·4 (1·5) | 4·4 (1·2) | 4·5 (1·3) | 4·8 (1·7) | 4·5 (1·7) | 4·4 (1·6) | 4·4 (1·7) | 5·5 (1·2) | 5·5 (1·2) |
| HPV16 status at enrollment | ||||||||||||
| Negative | 122 (63·5) | 116 (62·7) | 278 (66·3) | 265 (69·9) | 2098 (71·7) | 2091 (69·9) | 92 (84·4) | 60 (75·9) | 165 (76·4) | 176 (80·4) | 6669 (80·4) | 6682 (80·1) |
| Positive2 | 66 (34·4) | 63 (34·1) | 131 (31·3) | 106 (28·0) | 791 (27·0) | 849 (28·4) | 17 (15·6) | 18 (22·8) | 46 (21·3) | 39 (17·8) | 1553 (18·7) | 1565 (18·8) |
| HPV18 status at enrollment | ||||||||||||
| Negative | 129 (67·2) | 122 (65·9) | 290 (69·2) | 273 (72·0) | 2152 (73·5) | 2196 (73·4) | 100 (91·7) | 66 (83·5) | 180 (83·3) | 191 (87·2) | 7177 (86·5) | 7218 (86·5) |
| Positive2 | 57 (29·7) | 56 (30·3) | 118 (28·2) | 95 (25·1) | 710 (24·3) | 729 (24·4) | 9 (8·3) | 13 (16·5) | 33 (15·3) | 27 (12·3) | 1054 (12·7) | 1051 (12·6) |
1
Mean (SD);
2
Positive indicates positivity for HPV serology and/or DNA for the type in question; N (%).